<DOC>
	<DOC>NCT00500318</DOC>
	<brief_summary>This study evaluated the effect of inhaled aclidinium bromide on exercise endurance and in reducing resting and dynamic lung hyperinflation in patients with moderate to severe COPD. It was 9 weeks in duration, consisting of; a 2-week run-in period, 6 weeks of double-blind treatment, and a 1-week follow-up phone call. All patients meeting the eligibility criteria were randomized to one of two treatment groups: aclidinium bromide or placebo.</brief_summary>
	<brief_title>A Study of Exercise Endurance and Lung Hyperinflation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Bromides</mesh_term>
	<criteria>A diagnosis of stable moderate to severe COPD (GOLD 2006); postlevalbuterol FEV1 &gt;=30% and &lt; 80% predicted and FEV1/FVC&lt;70% predicted Current or former cigarette smoker Functional Residual Capacity (FRC) measured by body plethysmography &gt;= 120% of predicted value Baseline Dyspnea Index (BDI) focal score â‰¤ 7 at Visit 4 History of presence of asthma, allergic rhinitis, or atopy Hospitalization for acute COPD exacerbation in the 3 months prior to study entry Respiratory tract infection (including the upper respiratory tract) or COPD exacerbation in the 6 weeks prior to study entry Clinically significant respiratory conditions other than COPD Chronic use of oxygen therapy &gt;= 15 hours a day</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Bronchitis, Chronic; Emphysema</keyword>
</DOC>